Open-label randomised trial of Tolvaptan versus fluid restriction in hospitalised patients with moderate-severe hyponatraemia

托伐普坦与液体限制治疗中重度低钠血症住院患者的开放标签随机试验

• 批准号: nhmrc : 2005300
• 金额: $ 13.27万
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/open-label-randomised-severe-hyponatraemia/1780551
• 关键词: Open; label; randomised; trial; Tolvaptan

Low blood sodium level, known as hyponatraemia, is the most common electrolyte problem. It occurs in 15% of hospital patients, and can cause confusion, seizure and fatal brain swelling. Standard treatment for hyponatraemia is limiting oral fluid, but this is slow and not always effective. The drug tolvaptan works in mild hyponatraemia, but hasn't been formally tested in severe cases. We will compare benefits and risks of tolvaptan versus fluid restriction in patients with severe hyponatremia.

低血钠水平，称为低钠血症，是最常见的电解质问题。它发生在15%的医院患者中，并可导致混乱，癫痫发作和致命的脑肿胀。低钠血症的标准治疗是限制口腔液体，但这是缓慢的，并不总是有效的。药物托伐普坦对轻度低钠血症有效，但尚未在严重病例中进行正式测试。我们将比较托伐普坦与液体限制在重度低钠血症患者中的获益和风险。